Cleveland Biolabs (CBLI) 1.88 $CBLI Cleveland B
Post# of 273258
Posted On: 09/02/2016 1:12:29 PM
Cleveland Biolabs (CBLI) 1.88 $CBLI
Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress
Marketwire Canada - Mon Aug 15, 7:30AM CDT
BUFFALO, NY--(Marketwired - Aug 15, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2016.
CBLI: 1.88 (-0.11)
Global Mucositis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Cleveland BioLabs, Acta Dental, ARCA Biopharma - Research and Markets
BusinessWire - Fri Jun 10, 10:47AM CDT
Research and Markets has announced the addition of the "Mucositis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
ABIO: 2.84 (unch), CBLI: 1.88 (-0.11)
Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress
Marketwire Canada - Mon May 16, 6:30AM CDT
BUFFALO, NY--(Marketwired - May 16, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2016.
CBLI: 1.88 (-0.11)
22nd Century Launches Major New Initiative to Produce Medically-Important Marijuana Cannabinoids
BusinessWire - Thu May 12, 7:49AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and cannabis research, announced today that it is launching a major new initiative to produce medically important cannabinoids in plants other than cannabis - including tobacco plants.
XXII: 1.06 (+0.03), CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Webcast of Annual Meeting
Marketwired - Mon Apr 04, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its headquarters in Buffalo, NY.
CBLI: 1.88 (-0.11)
Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute
Marketwired - Tue Feb 09, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis. The data were published in Proceedings of the National Academy of Sciences of the United States of America (PNAS), the official journal of the United States National Academy of Sciences, based on studies conducted by scientists at RPCI and CBLI.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation
Marketwired - Tue Feb 02, 7:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naive patients with primary colorectal cancer who are recommended for surgery.
CBLI: 1.88 (-0.11)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 4.94 (-0.04), PCYC: 261.25 (+1.70), AMPE: 0.84 (-0.02), GSK: 44.24 (+1.26), MEIP: 1.77 (+0.03), AAAP: 34.26 (-0.15), MACK: 4.56 (-0.03), PGNX: 6.02 (-0.12), BLCM: 17.31 (-0.16), CYCC: 5.75 (+0.04), RXDX: 5.85 (-0.03), MRK: 62.79 (-0.11), AZN: 33.30 (+0.70), JUNO: 28.73 (-0.56), CBLI: 1.88 (-0.11), NVS: 79.22 (+0.95), CELGZ: 1.19 (+0.06)
Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation
Marketwired - Tue Jan 26, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Gets Orphan Status for Entolimod in EU
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 2:25PM CST
Cleveland BioLabs, Inc. (CBLI) announced that the EMA has granted orphan drug designation to its lead candidate, entolimod, for the treatment of acute radiation syndrome.
GILD: 77.00 (-0.42), MRK: 62.79 (-0.11), CBLI: 1.88 (-0.11), CELG: 105.58 (-0.79)
Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure
Marketwired - Thu Jan 21, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for treatment of acute radiation syndrome. Acute radiation syndrome comprises serious bone marrow, gastrointestinal, and other toxicities arising from exposure to high doses of radiation.
CBLI: 1.88 (-0.11)
Bone Marrow Transplantation Therapeutics Pipeline Report 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4wppsb/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bone Marrow Transplantation Overview - Therapeutics Development - Pipeline Products for Bone Marrow Transplantation - Overview - Pipeline Products for Bone Marrow Transplantation - Comparative Analysis - Bone Marrow Transplantation - Therapeutics under Development by Companies - Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes - Bone Marrow Transplantation - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bone Marrow Transplantation - Products under Development by Companies - Bone Marrow Transplantation - Products under Investigation by Universities/Institutes - Bone Marrow Transplantation - Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Taiga Biotechnologies, Inc. - Targazyme, Inc. For more information visit http://www.researchandmarkets.com/research/4w...one_marrow
MESO: 4.93 (-0.03), PSTI: 1.63 (-0.01), CGEN: 7.47 (+0.42), CBLI: 1.88 (-0.11)
Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute
Marketwired - Mon Dec 14, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI), Emory University and Roswell Park Cancer Institute (RPCI) today announced the publication of a study in Oncotarget demonstrating the ability of entolimod to suppress liver metastases in a preclinical model of uveal melanoma (UM). The study was led by Hans Grossniklaus MD, Professor of Ophthalmology, Director of the L.F. Montgomery Pathology Laboratory and Director of the Section of Ocular Oncology and Pathology at Emory Eye Center, Emory University, and Lyudmila Burdelya, PhD, Assistant Professor of Oncology in the Department of Cell Stress Biology at RPCI.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod
Marketwired - Mon Nov 30, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of two new patent applications by the U.S. Patent Office with claims that provide further protection for the Company's lead candidate, entolimod, as both a medical radiation countermeasure and an oncology therapeutic.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress
Marketwired - Thu Nov 05, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter and nine-month period ended September 30, 2015.
CBLI: 1.88 (-0.11)
Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5
Marketwired - Tue Oct 27, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2015, it will report its financial results for the third quarter and nine-month period ended September 30, 2015, and will host a conference call at 10:00 a.m. ET.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation
Marketwired - Wed Sep 16, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the publication in the scientific journal, PLOS ONE, of studies demonstrating the ability of entolimod to reduce radiation injury and improve survival when the drug is administered up to 48 hours after lethal radiation exposure in nonhuman primates.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces New Patents Strengthening Entolimod Portfolio
Marketwired - Tue Aug 18, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance or issuance of several new patents for entolimod in the U.S. and other countries, further bolstering its patent position.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress
Marketwire Canada - Mon Aug 15, 7:30AM CDT
BUFFALO, NY--(Marketwired - Aug 15, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2016.
CBLI: 1.88 (-0.11)
Global Mucositis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Cleveland BioLabs, Acta Dental, ARCA Biopharma - Research and Markets
BusinessWire - Fri Jun 10, 10:47AM CDT
Research and Markets has announced the addition of the "Mucositis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
ABIO: 2.84 (unch), CBLI: 1.88 (-0.11)
Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress
Marketwire Canada - Mon May 16, 6:30AM CDT
BUFFALO, NY--(Marketwired - May 16, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2016.
CBLI: 1.88 (-0.11)
22nd Century Launches Major New Initiative to Produce Medically-Important Marijuana Cannabinoids
BusinessWire - Thu May 12, 7:49AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and cannabis research, announced today that it is launching a major new initiative to produce medically important cannabinoids in plants other than cannabis - including tobacco plants.
XXII: 1.06 (+0.03), CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Webcast of Annual Meeting
Marketwired - Mon Apr 04, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its headquarters in Buffalo, NY.
CBLI: 1.88 (-0.11)
Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute
Marketwired - Tue Feb 09, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis. The data were published in Proceedings of the National Academy of Sciences of the United States of America (PNAS), the official journal of the United States National Academy of Sciences, based on studies conducted by scientists at RPCI and CBLI.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation
Marketwired - Tue Feb 02, 7:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naive patients with primary colorectal cancer who are recommended for surgery.
CBLI: 1.88 (-0.11)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 4.94 (-0.04), PCYC: 261.25 (+1.70), AMPE: 0.84 (-0.02), GSK: 44.24 (+1.26), MEIP: 1.77 (+0.03), AAAP: 34.26 (-0.15), MACK: 4.56 (-0.03), PGNX: 6.02 (-0.12), BLCM: 17.31 (-0.16), CYCC: 5.75 (+0.04), RXDX: 5.85 (-0.03), MRK: 62.79 (-0.11), AZN: 33.30 (+0.70), JUNO: 28.73 (-0.56), CBLI: 1.88 (-0.11), NVS: 79.22 (+0.95), CELGZ: 1.19 (+0.06)
Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation
Marketwired - Tue Jan 26, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Gets Orphan Status for Entolimod in EU
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 2:25PM CST
Cleveland BioLabs, Inc. (CBLI) announced that the EMA has granted orphan drug designation to its lead candidate, entolimod, for the treatment of acute radiation syndrome.
GILD: 77.00 (-0.42), MRK: 62.79 (-0.11), CBLI: 1.88 (-0.11), CELG: 105.58 (-0.79)
Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure
Marketwired - Thu Jan 21, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for treatment of acute radiation syndrome. Acute radiation syndrome comprises serious bone marrow, gastrointestinal, and other toxicities arising from exposure to high doses of radiation.
CBLI: 1.88 (-0.11)
Bone Marrow Transplantation Therapeutics Pipeline Report 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4wppsb/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bone Marrow Transplantation Overview - Therapeutics Development - Pipeline Products for Bone Marrow Transplantation - Overview - Pipeline Products for Bone Marrow Transplantation - Comparative Analysis - Bone Marrow Transplantation - Therapeutics under Development by Companies - Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes - Bone Marrow Transplantation - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bone Marrow Transplantation - Products under Development by Companies - Bone Marrow Transplantation - Products under Investigation by Universities/Institutes - Bone Marrow Transplantation - Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Taiga Biotechnologies, Inc. - Targazyme, Inc. For more information visit http://www.researchandmarkets.com/research/4w...one_marrow
MESO: 4.93 (-0.03), PSTI: 1.63 (-0.01), CGEN: 7.47 (+0.42), CBLI: 1.88 (-0.11)
Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute
Marketwired - Mon Dec 14, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI), Emory University and Roswell Park Cancer Institute (RPCI) today announced the publication of a study in Oncotarget demonstrating the ability of entolimod to suppress liver metastases in a preclinical model of uveal melanoma (UM). The study was led by Hans Grossniklaus MD, Professor of Ophthalmology, Director of the L.F. Montgomery Pathology Laboratory and Director of the Section of Ocular Oncology and Pathology at Emory Eye Center, Emory University, and Lyudmila Burdelya, PhD, Assistant Professor of Oncology in the Department of Cell Stress Biology at RPCI.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod
Marketwired - Mon Nov 30, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of two new patent applications by the U.S. Patent Office with claims that provide further protection for the Company's lead candidate, entolimod, as both a medical radiation countermeasure and an oncology therapeutic.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress
Marketwired - Thu Nov 05, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter and nine-month period ended September 30, 2015.
CBLI: 1.88 (-0.11)
Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5
Marketwired - Tue Oct 27, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2015, it will report its financial results for the third quarter and nine-month period ended September 30, 2015, and will host a conference call at 10:00 a.m. ET.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation
Marketwired - Wed Sep 16, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the publication in the scientific journal, PLOS ONE, of studies demonstrating the ability of entolimod to reduce radiation injury and improve survival when the drug is administered up to 48 hours after lethal radiation exposure in nonhuman primates.
CBLI: 1.88 (-0.11)
Cleveland BioLabs Announces New Patents Strengthening Entolimod Portfolio
Marketwired - Tue Aug 18, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance or issuance of several new patents for entolimod in the U.S. and other countries, further bolstering its patent position.
CBLI: 1.88 (-0.11)
(0)
(0)Scroll down for more posts ▼